E. M. Rettig, D. Souza, and G. , Epidemiology of head and neck cancer, Surg Oncol Clin, vol.24, pp.379-396, 2015.

J. Pignon, . Maître-a-le, E. Maillard, and J. Bourhis, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients, Radiother Oncol, vol.92, pp.4-14, 2009.

S. Marur and A. A. Forastiere, Head and neck cancer: changing epidemiology, diagnosis, and treatment, Mayo Clin Proc, vol.83, pp.489-501, 2008.

J. B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki et al., Platinum-based chemotherapy plus cetuximab in head and neck cancer, N Engl J Med, vol.359, pp.1116-1127, 2008.

A. A. Forastiere, B. Metch, D. E. Schuller, J. F. Ensley, L. F. Hutchins et al., Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study, J Clin Oncol, vol.10, pp.1245-1251, 1992.

R. Feldman, Z. Gatalica, J. Knezetic, S. Reddy, C. Nathan et al., Molecular profiling of head and neck squamous cell carcinoma, Head Neck, vol.38, pp.1625-1638, 2016.

J. A. Bonner, P. M. Harari, J. Giralt, R. B. Cohen, C. U. Jones et al., Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximabinduced rash and survival, Lancet Oncol, vol.11, issue.09, pp.70311-70311, 2010.

N. Van-der-linden, J. Buter, C. P. Pescott, R. I. Lalisang, J. P. De-boer et al., Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands, Eur Arch Otorhinolaryngol, vol.273, pp.455-464, 2016.

C. H. Chung, J. W. Lee, R. J. Slebos, J. D. Howard, J. Perez et al., A 3?-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, Ann Oncol, vol.25, pp.2230-2236, 2014.

L. J. Chin, E. Ratner, S. Leng, R. Zhai, S. Nallur et al., A SNP in a let-7 microRNA complementary site in the KRAS 3?UTR increases non-small cell lung cancer risk, Cancer Res, vol.68, pp.8535-8540, 2008.

K. De-ruyck, F. Duprez, F. L. Mbah, C. Rios-velazquez, E. Hoebers et al., A let-7 microRNA polymorphism in the KRAS 3?-UTR is prognostic in oropharyngeal cancer, Cancer Epidemiol, vol.38, pp.591-598, 2014.

B. C. Christensen, B. J. Moyer, M. Avissar, L. G. Ouellet, S. L. Plaza et al., A let-7 microRNAbinding site polymorphism in the KRAS 3? UTR is associated with reduced survival in oral cancers, Carcinogenesis, vol.30, pp.1003-1007, 2009.

J. B. Weidhaas, J. Harris, D. Schaue, A. M. Chen, R. Chin et al., The KRAS-variant and cetuximab response in head and neck squamous cell cancer: a secondary analysis of a randomized clinical trial, JAMA Oncol, vol.3, pp.483-491, 2017.

C. D. Lynggaard, M. H. Therkildsen, C. A. Kristensen, and L. Specht, The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort, Acta Oncol, vol.54, pp.1071-1075, 2015.

R. A. De-mello, S. Gerós, M. P. Alves, F. Moreira, I. Avezedo et al., Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution, PloS One, vol.9, 2014.

P. Chang, Y. Hsieh, M. Chen, C. Tzeng, P. Chu et al., Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular, J Chin Med Assoc, vol.73, issue.10, pp.70064-70066, 2010.

T. Yoshino, Y. Hasegawa, S. Takahashi, N. Monden, A. Homma et al., Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial, Jpn J Clin Oncol, vol.43, pp.524-531, 2013.

D. Soulières, J. L. Aguilar, E. Chen, K. Misiukiewicz, S. Ernst et al., Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen, BMC Cancer, vol.16, 2016.

R. S. Herbst, M. Arquette, D. M. Shin, K. Dicke, E. E. Vokes et al., Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck, J Clin Oncol, vol.23, pp.5578-5587, 2005.

H. Ying, F. Wang, B. He, Y. Pan, T. Gao et al., The involvement of Kras gene 3?-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis, OncoTargets Ther, vol.7, pp.1487-1496, 2014.

S. Zhang and J. Shi, rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: a meta-analysis, J Cancer Res Ther, vol.12, p.699, 2016.

K. M. Smits, T. Paranjape, S. Nallur, K. Wouters, M. P. Weijenberg et al., A let-7 microRNA SNP in the KRAS 3?UTR is prognostic in early-stage colorectal cancer, Clin Cancer Res, vol.17, pp.7723-7731, 2011.

F. Graziano, E. Canestrari, F. Loupakis, A. Ruzzo, N. Galluccio et al., Genetic modulation of the Let-7 microRNA binding to KRAS 3?-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan, Pharmacogenom J, vol.10, pp.458-464, 2010.

A. Hollestelle, F. H. Van-der-baan, A. Berchuck, S. E. Johnatty, K. K. Aben et al., No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, Gynecol Oncol, vol.141, pp.386-401, 2016.

T. Paranjape, H. Heneghan, R. Lindner, F. K. Keane, A. Hoffman et al., A 3?-untranslated region KRAS variant and triple-negative breast cancer: a casecontrol and genetic analysis, Lancet Oncol, vol.12, issue.11, pp.70044-70048, 2011.

E. H. Crowley, S. Arena, S. Lamba, D. Nicolantonio, F. Bardelli et al., Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels, Hum Mutat, vol.35, pp.208-214, 2014.